John E. Palardy

1.8k citations

30 papers · 1.4k indexed · 1 hit paper · h-index 20

Impact in

Immunology top 5%
- Immune Response and Inflammation
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
Clinical Biochemistry top 2%
- Advanced Glycation End Products research

Papers in

Microbiology 7
- Antimicrobial Peptides and Activities 4
- Bacterial Infections and Vaccines 3
Immunology 22
- Immune Response and Inflammation 21

Co-authors: Steven M. Opal Nicolas A. Parejo John P. Pribble Patrick J. Scannon Mark White Jon H. Lemke Jean‐Louis Vincent Stephen F. Carroll
Journals: The Journal of Infectious Diseases (10 papers)Shock (5 papers)Critical Care Medicine (4 papers)Vaccine (2 papers)Antimicrobial Agents and Chemotherapy (2 papers)
Partner nations: United States Canada Belgium

In The Last Decade

John E. Palardy

30 papers receiving 1.4k citations

Hit Papers

align trajectories log scale

Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock 1999 · 505 citations

Peers

Countries citing papers authored by John E. Palardy

Since Specialization

Citations

This map shows the geographic impact of John E. Palardy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John E. Palardy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John E. Palardy more than expected).

Fields of papers citing papers by John E. Palardy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John E. Palardy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John E. Palardy. The network helps show where John E. Palardy may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John E. Palardy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John E. Palardy Line = papers co-authored together John E. Palardy links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	PHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSIS Shock ·Steven M. Opal, James L. Ellis, Vipin Suri, Johannes Freudenberg, George P. Vlasuk, Yong Li, Abdullah Chahin, John E. Palardy, Franklin Luis dos Santos, Andrei Krylov, 吉祝美, Noubar Kessimian	2015	44
2	CD28 Homodimer Interface Mimetic Peptide Acts as a Preventive and Therapeutic Agent in Models of Severe Bacterial Sepsis and Gram-Negative Bacterial Peritonitis The Journal of Infectious Diseases ·Girish Ramachandran, Raymond Kaempfer, Chun‐Shiang Chung, Anat Shirvan, Abdullah Chahin, John E. Palardy, Nicolas A. Parejo, Yaping Chen, Borra D., Gila Arad, Dalia Hillman, Ronen Shemesh, William C. Blackwelder, Alfred Ayala, Alan S. Cross, Steven M. Opal	2014	30
3	A Monoclonal Antibody Against RAGE Alters Gene Expression and is Protective in Experimental Models of Sepsis and Pneumococcal Pneumonia Shock ·Eirini Christaki, Steven M. Opal, James C. Keith, Alara Er, John E. Palardy, Nicolas A. Parejo, Hadiza Aliyu-Amoo, Nicole Piche‐Nicholas, Lioudmila Tchistiakova, George P. Vlasuk, Kathleen Shields, Jeffrey L. Feldman, Edward R. LaVallie, Maya Arai, William Mounts, Debra D. Pittman	2011	44
4	Estrogen Receptor β Agonism Increases Survival in Experimentally Induced Sepsis and Ameliorates the Genomic Sepsis Signature: A Pharmacogenomic Study The Journal of Infectious Diseases ·Eirini Christaki, Steven M. Opal, James C. Keith, Xincheng Lin, John E. Palardy, Nicolas A. Parejo, Edward R. LaVallie, Pip McDonald, William Mounts, Michael S. Malamas, Richard E. Mewshaw, Heather A. Harris, George P. Vlasuk	2010	36
5	Detoxified Endotoxin Vaccine (J5dLPS/OMP) Protects Mice Against Lethal Respiratory Challenge with Francisella tularensis SchuS4 Vaccine ·Stephen H. Gregory, Wilbur H. Chen, Stephanie Mott, John E. Palardy, Franklin Luis dos Santos, B Bensaude-Vincent, Christine A. Anderson, Andrew W. Artenstein, Steven M. Opal, Alan S. Cross	2010	10
6	Inter-α Inhibitor Proteins Shock ·Steven M. Opal, Yow‐Pin Lim, Patricia Cristofaro, Andrew W. Artenstein, Noubar Kessimian, Amabilly Dias Vieira Nazário Alves, Nicolas A. Parejo, John E. Palardy, Patricia K. Jeys	2010	28
7	Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection Critical Care ·Emily Lutterloh, Steven M. Opal, Debra D. Pittman, James C. Keith, Xiangyang Tan, Brian M. Clancy, Helen Palmer, Kim Milarski, Ying Sun, John E. Palardy, Franklin Luis dos Santos, Noubar Kessimian	2007	135
8	Longitudinal studies of inter-alpha inhibitor proteins in severely septic patients: A potential clinical marker and mediator of severe sepsis* Critical Care Medicine ·Steven M. Opal, Yow‐Pin Lim, Patricia K. Jeys, Lyle L. Moldawer, John P. Pribble, John E. Palardy, Sonia Souza	2007	39
9	THE ACTIVITY OF PATHWAY-SELECTIVE ESTROGEN RECEPTOR LIGANDS IN EXPERIMENTAL SEPTIC SHOCK Shock ·Steven M. Opal, John E. Palardy, Patricia Cristofaro, Nicolas A. Parejo, Jhung W. Jhung, James C. Keith, Edisson Giovanny García García, 许孙鑫, Robert J. Steffan, Christopher C. Chadwick, Douglas C. Harnish	2005	7
10	Active Immunization with a Detoxified Endotoxin Vaccine Protects against Lethal Polymicrobial Sepsis: Its Use with CpG Adjuvant and Potential Mechanisms The Journal of Infectious Diseases ·Steven M. Opal, John E. Palardy, Wilbur H. Chen, Nicolas A. Parejo, Apurba K. Bhattacharjee, Alan S. Cross	2005	26
11	Chloroquine Enhances Survival inBacillusanthracisIntoxication The Journal of Infectious Diseases ·Andrew W. Artenstein, Steven M. Opal, Patricia Cristofaro, John E. Palardy, Nicolas A. Parejo, Michael D. Green, Jhung W. Jhung	2004	25
12	Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects Vaccine ·Alan S. Cross, Steven M. Opal, John E. Palardy, Joseph J. Drabick, H. Shaw Warren, Pedro Áureo Pessoa Ribeiro, Pamela Cook, Apurba K. Bhattacharjee	2003	27
13	Effect of anti-CD14 monoclonal antibody on clearance of Escherichia coli bacteremia and endotoxemia Critical Care Medicine ·Steven M. Opal, John E. Palardy, Nicolas A. Parejo, Maomao HAN	2003	24
14	Correlation between Mortality and the Levels of Inter‐Alpha Inhibitors in the Plasma of Patients with Severe Sepsis The Journal of Infectious Diseases ·Yow‐Pin Lim, Krešo Bendelja, Steven M. Opal, Patricia K. Jeys, Douglas C. Hixson, John E. Palardy	2003	95
15	Orally Administered Recombinant Human Interleukin‐11 Is Protective in Experimental Neutropenic Sepsis The Journal of Infectious Diseases ·Steven M. Opal, James C. Keith, R. M. Kimble, John E. Palardy, Nicolas A. Parejo, 加瀬友喜, Nathan Mark Thomas	2002	21
16	EVALUATION OF THE SAFETY OF RECOMBINANT P-SELECTIN GLYCOPROTEIN LIGAND-IMMUNOGLOBULIN G FUSION PROTEIN IN EXPERIMENTAL MODELS OF LOCALIZED AND SYSTEMIC INFECTION Shock ·Steven M. Opal, Joseph P. Sypek, James C. Keith, Marvellous Mhloyi, John E. Palardy, Nicolas A. Parejo	2001	13
17	Active Immunization with a DetoxifiedEscherichia coliJ5 Lipopolysaccharide Group B Meningococcal Outer Membrane Protein Complex Vaccine Protects Animals from Experimental Sepsis The Journal of Infectious Diseases ·Nick Kleese, Steven M. Opal, H. Shaw Warren, John E. Palardy, K. Rajam, Nicolas A. Parejo, Apurba K. Bhattacharjee	2001	38
18	Recombinant Human Interleukin‐11 Has Anti‐inflammatory Actions Yet Does Not Exacerbate SystemicListeriaInfection The Journal of Infectious Diseases ·Steven M. Opal, James C. Keith, John E. Palardy, Nicolas A. Parejo	2000	12
19	Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock The Journal of Infectious Diseases ·Steven M. Opal, Patrick J. Scannon, Jean‐Louis Vincent, Mark White, Stephen F. Carroll, John E. Palardy, Nicolas A. Parejo, John P. Pribble, Jon H. Lemke Hit paper breakdown →	1999	505
20	Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge Critical Care Medicine ·Charles J. Fisher, M N Marra, John E. Palardy, C. Randall Marchbanks, Randy W. Scott, Steven M. Opal	1994	92

About John E. Palardy

John E. Palardy is a scholar working on Microbiology, Immunology, Clinical Biochemistry, Oncology and Small Animals, having authored 30 papers that have together received 1.4k indexed citations. Recurring topics across this work include Immune Response and Inflammation (21 papers), Neutropenia and Cancer Infections (6 papers), Sepsis Diagnosis and Treatment (5 papers), Antimicrobial Peptides and Activities (4 papers), Bacillus and Francisella bacterial research (4 papers), Pneumonia and Respiratory Infections (3 papers), Estrogen and related hormone effects (3 papers) and Bacterial Infections and Vaccines (3 papers). The work is most often cited by research in Immunology (617 citations), Clinical Biochemistry (175 citations), Critical Care and Intensive Care Medicine (99 citations), Microbiology (86 citations) and Epidemiology (475 citations). John E. Palardy has collaborated with scholars based in United States, Canada and Belgium. Frequent co-authors include Steven M. Opal, Nicolas A. Parejo, John P. Pribble, Patrick J. Scannon, Mark White, Jon H. Lemke, Jean‐Louis Vincent, Stephen F. Carroll, James C. Keith and Yow‐Pin Lim. Their work appears in journals such as The Journal of Infectious Diseases, Shock, Critical Care Medicine, Vaccine and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact